Potential Efficacy of Anti-PD-1 or PD-L1 Antibody Treatments for Gynecologic Cancers

Journal Title: Women's Health – Open Journal - Year 2017, Vol 3, Issue 3

Abstract

Programmed cell death-1 (PD-1; CD279) is an immunosuppressive co-inhibitory molecule that belongs to the CD28 family of receptors on T-cells. It was discovered by Ishida et al in 1992.1 The most important peripheral regulatory pathway is the interaction between the PD-1 receptor, expressed on T-cells, and programmed cell death ligands-1 and 2 (PD-L1 and PD-L2) on the cancer cell surface.2 This immune checkpoint exists in a normal physiological state to protect against autoimmunity and inflammation. In a neoplastic state, dysfunction of these immune checkpoint proteins can lead to tumor tolerance and eventually allow tumors to ‘escape’ from the immune system. PD-1 blockage enhances the proliferation of transferred T-cells at the tumor site. In addition, the combination of adoptive T-cell transfer and anti-PD-1 antibody results in significant inhibition of tumor progression.3 These therapeutic effects of PD-1 blockage require the INF-γ signal. Targeting the molecules that regulate the immune response using the new drug nivolumab, an anti-PD-1 antibody has been the subject of much research and has yielded some promising and exciting results.

Authors and Affiliations

Masafumi Koshiyama

Keywords

Related Articles

The Stigma of Rape: Gendered Victimization

The problem of rape is as old as civilization and it is a universal concern of great magnitude. Rape is classified as a violent crime in all nations and attracts strong penal action. This however has not deterred sexual...

Prevalence of Urogynaecological Symptoms in Survivors of Cervical Cancer in a Tertiary Care Gynaecologic Oncology Clinic of a Developing Country

Background: A lot of research has focussed on bowel symptoms but data is relatively scarce on exact burden of urinary subset of urogynaecological symptoms in survivors of cervical cancer. Aims and objectives: To find out...

Breast Cancer Screening and the AsianAmerican and Pacific Islander Communities

Years before the new breast cancer screening was established, whenever you hear about breast cancer, the buzz words was “early detection saves lives.” Translating this hype is easy: when breast cancer was found in its ea...

The Medicalisation of Menstruation: Its Scope and Limits

Conventional western medicine has very determinately ‘technologized’ its approach to health and the human body. While there are many benefits evinced from this conventional orientation, there are also disconcerting liabi...

Cesarean Section and Associated Surgeries: Feasibility and Surgical Outcomes

Cesarean section being the most commonly performed surgery in Egypt, the incidents of cesarean delivery in general hospitals were found to be nearly 50.6%, whereas, in private hospitals such cases were reported to be muc...

Download PDF file
  • EP ID EP554947
  • DOI 10.17140/WHOJ-3-e013
  • Views 120
  • Downloads 0

How To Cite

Masafumi Koshiyama (2017). Potential Efficacy of Anti-PD-1 or PD-L1 Antibody Treatments for Gynecologic Cancers. Women's Health – Open Journal, 3(3), 21-23. https://europub.co.uk/articles/-A-554947